Renowned pulmonologist, Imre Noth, MD, and scleroderma expert rheumatologist, Elizabeth Volkmann, MD, MS, discuss the importance of screening patients with systemic sclerosis (SSc) to identify those at risk for interstitial lung disease (ILD) even before respiratory symptoms are reported. Risk factors, burden of disease, and comorbidities associated with SSc-ILD are presented. This rare multisystemic disease affects the lungs, heart, and kidneys, in addition to the skin and gastrointestinal tract. Careful monitoring and ongoing evaluation are required to minimize lung complications. The latest first-line treatments and combination strategies are reviewed, along with data of FDA-approved targeted therapies as the faculty provide insights to individualize treatment so as to improve patient outcomes. Faculty case presentations describe treatment strategies and address how best to optimize clinician-patient communication in this innovative education format.
Editor’s Note: The faculty for this enduring activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.
2.00 AMA PRA Category 1 CreditsTM
This activity was developed for pulmonologists, radiologists, rheumatologists, dermatologists, and primary care physicians, as well as other clinicians who care for patients with interstitial lung disease.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Imre Noth, MD
Professor of Medicine
Chief, Division of Pulmonary and Critical Care
University of Virginia
Elizabeth Volkmann, MD
Director, UCLA Scleroderma Program
Co-Director, CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California
Los Angeles, California